REMIT-UC: Tofacitinib study 334 w/ Ulcerative Colitis:Clinical remission in 35%, Endoscopic remission in ~24%; & low
Tweet Content
REMIT-UC: Tofacitinib study 334 w/ Ulcerative Colitis:Clinical remission in 35%, Endoscopic remission in ~24%; & low risk (per/100PY) of serious infections (2.1), H zoster (0.5), & VTE (1.1). Loss of response in 45%, but recaptured 55% w/ dose escalation https://t.co/KgSrKBbv40 https://t.co/M74l4tOA3U
Links
Show on Archive Page
On
Display in Search Results
On
PDQ
Off